PDCD1 and neoplasm: In particular, PD-1-PD-L1 inhibitors enhanced the cytolytic activity of tumor-specific T cells, reduced suppressive cytokine IL-10 production, whereas enhanced pro-inflammatory cytokine synthesis, promoted the presence of Teffs and diminished the numbers and suppressive function of Tregs in the tumor site (35–38).